Wyeth seeks $960 million in damages from Sun in Protonix case

16 Feb 2012 Evaluate

Wyeth has claimed $960 million from Sun Pharmaceutical Industries for alleged patent violation in launching a generic version of acid reflux drug Protonix in the United States. The original patent relating to Protonix, known chemically as pantoprazole sodium, is held by Swiss drugmaker Nycomed and was licensed to Wyeth, which is now owned by Pfizer.

In this regard, Nycomed, owned by Japan's Takeda Pharmaceutical Co. and Wyeth have filed the lawsuit in the US District Court in New Jersey against Sun Pharmaceutical and Teva Pharmaceutical Industries.

Sun launched its generic version of Protonix tablets in January 2008 after Teva Pharmaceutical Industries and its US subsidiary began selling the drug in December 2007.

The pharmaceuticals business of the Wyeth comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products.

Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×